WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • May 15th, 2018 • Tapimmune Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of May 14, 2018, is by and between TapImmune Inc., a Nevada corporation (the “Company”) and the undersigned holder (the “Holder”) of that certain Series D Warrant to Purchase Common Stock issued by the Company to the Holder, which warrant is exercisable at an exercise price (the “Series D Warrant Exercise Price”) of $9.00 per share (the “Series D Warrant”).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • May 15th, 2018 • Tapimmune Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of May 14, 2018, is by and between TapImmune Inc., a Nevada corporation (the “Company”) and the undersigned holder (the “Holder”) of those certain (i) Series D Warrant to Purchase Common Stock issued by the Company to the Holder, which warrant is exercisable at an exercise price (the “Series D Warrant Exercise Price”) of $9.00 per share (the “Series D Warrant”); (ii) Series E Warrant to Purchase Common Stock issued by the Company to the Holder, which warrant is exercisable at an exercise price (the “Series E Warrant Exercise Price”) of $15.00 per share (the “Series E Warrant”); and (iii) Series F Warrant to Purchase Common Stock issued by the Company to the Holder, which warrant is exercisable at an exercise price (the “Series F Warrant Exercise Price”) of $7.20 per share (the “Series F Warrant”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • May 15th, 2018 • Tapimmune Inc. • Pharmaceutical preparations • Florida
This Common Stock Purchase Agreement (this “Agreement”) is dated as of May 14, 2018, by and among TapImmune, Inc., a Nevada corporation (the “Company) and Eastern Capital Limited (the “Purchaser”).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • May 15th, 2018 • Tapimmune Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of May 14, 2018, is by and between TapImmune Inc., a Nevada corporation (the “Company”) and Brio Capital Master Fund Ltd. (the “Holder”) of those certain (i) Series C Warrant to Purchase Common Stock issued by the Company to the Holder, a portion of which warrant is exercisable at an exercise price (the “Series C Warrant Exercise Price”) of $6.00 per share (the “Series C Warrant”); (ii) Series D Warrant to Purchase Common Stock issued by the Company to the Holder, a portion of which warrant is exercisable at an exercise price (the “Series D Warrant Exercise Price”) of $9.00 per share (the “Series D Warrant”); (iii) Series E Warrant to Purchase Common Stock issued by the Company to the Holder, a portion of which warrant is exercisable at an exercise price (the “Series E Warrant Exercise Price”) of $15.00 per share (the “Series E Warrant”); and (iv) Series F Warrant to Purchase Common Stock issued by the Company to the Holder,
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • May 15th, 2018 • Tapimmune Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of May 14, 2018, is by and between TapImmune Inc., a Nevada corporation (the “Company”) and the undersigned holder (the “Holder”) of that certain Series C Warrant to Purchase Common Stock issued by the Company to the Holder, which warrant is exercisable at an exercise price (the “Series C Warrant Exercise Price”) of $6.00 per share (the “Series C Warrant”).
